Director — Robert B. Catell, Joseph D. Ceccoli, Dr. Yacov Shamash, Richard Shorten, Todd Larsen, Lok Lee: Three directors resigned and were immediately replaced by new appointees, including a strategic advisor with significant affiliations to a major shareholder, indicating a board reshuffle rather than a loss of senior executive management.

Unregistered Sales of Equity Securities To the extent required by

Termination of a Material Definitive Agreement. As previously disclosed, on September 29, 2025, the Company entered into a Strategic Digital Assets Services Agreement (the “Digital Services Agreement”) with Cypress LLC, a Puerto Rico limited liability company (“Cypress Digital”), pursuant to which the Company appointed Cypress Digital to provide certain discretionary asset management services to the Company. On September 29, 2025, the Company also entered into a Strategic Advisor Agreement (t…

Entry into a Material Definitive Agreement. To the extent required by

Chairman and Director — Josh Kruger: Josh Kruger resigned as Chairman and director of the Company.

Regulation FD Disclosure. On July 13, 2026, the Company issued a press release announcing its receipt of the Delisting Notice. A copy of the press release is being furnished herewith as Exhibit 99.1. The information under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by refe…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 10, 2026, BNB Plus Corp. (the “Company”) received written notification (the “Delisting Notice”) from The Nasdaq Stock Market (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common stock, par value $0.001 per share (“Common Stock”), and suspend trading of its Common Stock at the open of trading on July 14, 2026. As previously reported on Ma…

Entry into a Material Definitive Agreement. On June 29, 2026, the Company entered into an amendment, effective June 23, 2026, to the Registration Rights Agreement dated May 26, 2026 (the “Agreement”) with purchasers holding 50.1% or more of the Registrable Securities (as such term is defined in the Agreement). The definition of Filing Date in the Agreement was amended to extend such date to 30 calendars days following the date on which all purchasers of Registrable Securities have closed (the…

Unregistered Sales of Equity Securities On June 23, 2026 and June 24, 2026, the Company closed the transactions contemplated by Inducement Agreements entered into between the Company and three Exchanging Holders, and sold and issued to the Exchanging Holders 1,318,936 shares of Series B-1 Preferred Stock, 1,195,735 shares of Series B-2 Preferred Stock, and Series B-2 Prefunded Warrants to purchase 2,303,620 shares of Series B-2 Preferred Stock, for aggregate gross proceeds of $1.54 million. I…

Unregistered Sales of Equity Securities On May 28, 2026, the Company closed the transaction contemplated by the SPA and sold and issued to the Purchaser, at an offering price of $1.05 per share, 2,380,953 shares of Series B-1 Preferred Stock and Common Warrants to purchase 2,380,953 shares of Common Stock. Gross proceeds from the SPA totaled $2.5 million. On May 31, 2026, the Company entered into an Inducement Agreement with an Exchanging Holder for an exercise of Series E Warrants in an aggr…

Entry into a Material Definitive Agreement. Private Placement and Inducement Transaction On May 26, 2026, BNB Plus Corp., a Delaware corporation (the “Company”), entered into agreements to issue in one or more offerings up to an aggregate amount of $5 million (the “Aggregate Offering Amount”) of the Company’s securities in a convertible preferred equity private placement financing pursuant to: (1) a Securities Purchase Agreement (the “SPA”) with accredited investors (“Purchasers”) whereby Pur…

Unregistered Sales of Equity Securities. To the extent required by

Material Modification to Rights of Security Holders. To the extent required by

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. BNB Plus Corp. (the “Company”) received written notice dated March 20, 2026 (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company no longer satisfies the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires li…

Director — James Haft: Appointment of James Haft as a director to fill a vacancy.

director — Elizabeth M. Schmalz Shaheen: Ms. Schmalz Shaheen resigned as a director of the Company.

Chairman and Director — Joshua Kruger: Mr. Joshua Kruger was appointed as the new Chairman and Director, replacing Judith Murrah.

Entry into a Material Definitive Agreement On November 4, 2025, Applied DNA Sciences, Inc. (the “ Company ”) entered into an At The Market Offering Agreement (the “ Agreement ”) with Lucid Capital Markets, LLC, as sales agent (the “ Agent ”), pursuant to which the Company may, from time to time, offer and sell shares of its common stock, par value $0.001 per share, with an aggregate offering price of up to $8,157,932 (the “ Shares ”) through the Agent. The offer and sale of the Shares made pu…

Other Events. On October 22, 2025, Applied DNA Sciences, Inc. (the “Company”) announced the closing of its previously announced private placement offerings in which, (i) the Company sold to certain accredited investors, at an offering price of $3.32 per share, an aggregate of 4,620,485 shares of common stock of the Company, par value $0.001 per share (the “Common Stock”), and/or prefunded warrants in lieu thereof (with such prefunded warrants having an exercise price of $0.0001 per share), an…

Costs Associated with Exit or Disposal Activities. On September 30, 2025, the Board of Directors of Applied DNA Sciences, Inc. (the “ Company ”) authorized, and its officers implemented, a restructuring plan pursuant to which the Company will reduce overall operating expenses to focus resources on its previously announced BNB-focused treasury strategy. The restructuring plan includes a reduction of the Company’s current workforce by sixteen employees, or approximately 60%. The Company estimat…

Regulation FD Disclosure. On October 6, 2025, the Company issued a press release announcing that it will change its ticker symbol on the Nasdaq Capital Market from "APDN" to "BNBX" effective at the opening of trading on Tuesday, October 7, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of…

Chief Executive Officer and President — Judith Murrah: Ms. Murrah stepped down from her positions as CEO and President, with Clay D. Shorrock appointed as the new CEO.

Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company.

Entry into a Material Definitive Agreement. Securities Purchase Agreement On September 29, 2025, Applied DNA Sciences, Inc., a Delaware corporation (the “Company”) entered into a securities purchase agreement (the “Cash Securities Purchase Agreement”) with certain accredited investors (the “Cash Purchasers”) pursuant to which the Company agreed to sell and issue to the Cash Purchasers in a private placement offering (the “Cash Offering”), at an offering price of $3.32 per share, an aggregate…

Other Information. In connection with the Offering and related transactions described herein, the Company is filing certain updated business description disclosure for the purpose of supplementing and updating disclosures contained in the Company’s prior public filings, including those discussed under the heading “Item 1. Business” in the Company’s Annual Report on Form 10-K for the year ended September 30, 2024, filed with the SEC on December 17, 2024. The supplemental updated business descr…